You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Abbvie to continue manufacturing component for lymphoma drug
Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense
Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures
MA Activity The Big Story In Mature Online Video Platform Market
Martina Cheung Backs The Quality Program
Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.
The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.
Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.